Showing results (91-100 of 137) with videos related to
Sort By:
Pageof 14
Journal of Medical Virology|July 19, 2023
HCV spontaneous clearers showed low senescence profile in people living with HIV under long ARTVioleta Lara-Aguilar, Celia Crespo-Bermejo, Manuel Llamas-Adán, et al.AIDS and Behavior|April 4, 2025
Drug Addiction in Gay and Bisexual Men Living with HIV Engaged in Sexualized Drug Use: Recent Drug Use, Polydrug and Depressive Symptoms as PredictorsMar J F Ollero, Pablo Ryan, Helen Dolengevich-Segal, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 9, 2020
Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNADavid Smookler, Aaron Vanderhoff, Mia J Biondi, et al.Immunity & Ageing : I & A|November 18, 2023
Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health riskRubén Martín-Escolano, Erick Joan Vidal-Alcántara, Javier Crespo, et al.Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|November 9, 2023
Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in MadridLuz Martín-Carbonero, Ángela Gutierrez, Otilia Bisbal, et al.Journal of Clinical Medicine|July 9, 2020
Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected PatientsPaula Martínez-Román, María Rosa López-Huertas, Celia Crespo-Bermejo, et al.Journal of Infection and Public Health|June 12, 2024
Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective studyMaría José Muñoz-Gómez, Pablo Ryan, Marta Quero-Delgado, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 9, 2023
Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIVVioleta Lara-Aguilar, Daniel Valle-Millares, Celia Crespo-Bermejo, et al.Plos One|February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.Plos One|October 12, 2016
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.Pageof 14